0.2905

2.19% -0.0065

After Hours: .307 0.0165 +5.68%

Qualigen Therapeutics Inc (QLGN)

Overview News Price History Discussions Forecast Stock Split

Qualigen Therapeutics Inc stock is currently priced at $0.2905, with a 24-hour trading volume of 9,216. It has seen a -2.19% decreased in the last 24 hours and a -27.56% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.3043 pivot point. If it approaches the $0.2897 support level, significant changes may occur.

Previous Close:

$0.297

Open:

$0.3

24h Volume:

9,216

Market Cap:

$1.83M

Revenue:

$4.79M

Net Income/Loss:

$-13.42M

P/E Ratio:

-0.0723

EPS:

-4.02

Net Cash Flow:

$-10.30M

1W Performance:

-8.65%

1M Performance:

-27.56%

6M Performance:

-60.59%

1Y Performance:

-67.63%

1D Range:

$0.2905

$0.319

52W Range:

$0.2831

$1.26

Qualigen Therapeutics Inc Stock (QLGN) Company Profile

Name

Qualigen Therapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

760 918 9165

Address

2042 Corte Del Nogal, Carlsbad

Employee

Twitter

Next Earnings Date

2024-05-14

Latest SEC Filings

QLGN's Discussions on Twitter

Qualigen Therapeutics Inc Stock (QLGN) Latest News

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

GlobeNewswire Inc.

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

GlobeNewswire Inc.

Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket

Benzinga

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

GlobeNewswire Inc.

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

GlobeNewswire Inc.

Qualigen Therapeutics Inc Stock (QLGN) Financials Data

Qualigen Therapeutics Inc (QLGN) Revenue 2024

QLGN reported a revenue (TTM) of $4.79 million for the quarter ending June 30, 2022, a +0.62% rise year-over-year.

Qualigen Therapeutics Inc (QLGN) Net Income 2024

QLGN net income (TTM) was -$13.42 million for the quarter ending December 31, 2023, a +28.02% increase year-over-year.

Qualigen Therapeutics Inc (QLGN) Cash Flow 2024

QLGN recorded a free cash flow (TTM) of -$10.30 million for the quarter ending December 31, 2023, a +22.22% increase year-over-year.

Qualigen Therapeutics Inc (QLGN) Earnings per Share 2024

QLGN earnings per share (TTM) was -$2.66 for the quarter ending December 31, 2023, a +45.38% growth year-over-year.

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.